Bengaluru: With the main drugstore standard control organizations give approval for the limited use of the original Zycov-D, DNA Covid-19 vaccine, in an emergency situation in India for children aged 12 years and over, Belparavi Hospital tested has been flooded with calls from parents who are looking for inoculation for their children.
Jeevan Rekha Hospital in Bellagavi is one of the 25 centers across the country where clinical trials for ZY-COV-D are carried out.
The vaccine is said to be the first DNA vaccine against Sarscov2 in the world.
It was developed by Cadila Healthcare in partnership with the Biotechnology Department (DBT) under the center mission of Covid-19 Surakha.
Dr.
Amit Bhate, Director, Jeevan Rikha Hospital and the main investigator of this study, said parents wanted to make their children vaccinated in front of the possible third infection wave.
He said Jeevan Rikha got at least 10 calls a day with old people who were desperately looking for vaccines for their children.
In accordance with Covid-19 war room data, until Sunday (August 22), 2.2 lakh children in the age group of 10-19 years have been tested positively disease in Karnataka, and 90 of them have given up on infection.
Authorization of emergency use for Zycov-D was issued on August 20, based on temporary results from phase-III clinical trials involving more than 28,000 volunteers.
The results of the study showed primary efficacy of 66.6%.
“Because our hospital is only part of the clinical trial, we don’t have a vaccine dose with us.
This is what we tell parents who call us.
Parents must wait until the government provides a dose,” Dr.
Bhate told Toi.
No side effects of 20 children in the age group 12-18 are part of the trial at the Hospital of the Belaghavi.
The trial was carried out between February and April this year.
The dose consisting of 0.5ml vaccine is intradermal, and children do not suffer from the main side effects, said Dr.
Bhat.
Three doses of vaccines are given on day 0, day 28 and day 56.
Hospitals are also part of Covaxin Bharat Biotech clinical trials for adults and some children who participate in the Zydus Cadila trial owned by parents who have submitted themselves for clinical trials Covaxin.
“These children are volunteer for trials.
In accordance with the protocol, audio and video approval is needed before testing the vaccine on them.
Parents of all children are advised in vaccines and are fully aware of the risks involved with clinical trials.
So far, there are no side effects Seen among children who take vaccines.
Some children experience pain in injected arms and lightweight fever.
No one shows an allergic reaction or anaphylaxis, “said Dr.
Bhate.
The follow-up test in the hospital will follow up on the health of these children for 18 months to monitor the immune response to the novel Coronaviru S.
Children who are part of the clinical trial must visit hospitals regularly for follow-up tests which are the majority of children Children who participate in clinical trials are those from Bellagavi themselves.
However, some came from neighboring Hubballi and Dharwad.
During the trial, a single dose vial of the Zydus Cadila 0.5ml vaccine was used.
Vaccines need to be stored at 2-8 degrees Celsius.